Takeda signs RNAi deal with Alnylam
In a new five-year deal, Alnylam has granted Takeda Pharmaceutical worldwide, nonexclusive rights to an RNAi-based therapeutics technology in the areas of metabolic diseases and cancer, with an option to include additional indications at a later date.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com